中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Overcoming multidrug resistance (MDR) in cancer by nanotechnology

文献类型:期刊论文

作者Bu HuiHui; Gao Yu; Li YaPing
刊名SCIENCE CHINA-CHEMISTRY
出版日期2010-11
卷号53期号:11页码:2226-2232
关键词nanotechnology nanoparticles multidrug resistance chemotherapeutic drugs cancer drug delivery system
ISSN号1674-7291
DOI10.1007/s11426-010-4142-5
文献子类Review
英文摘要The emerging nanotechnology-based drug delivery holds tremendous potential to deliver chemotherapeutic drugs for treatment of multidrug resistance (MDR) cancer. This drug delivery system could improve the pharmacokinetic behavior of antitumor drugs, deliver chemotherapeutic drugs to target sites, control release of drugs, and reduce the systemic toxicity of drugs in MDR cancer. This review addresses the use of nanotechnology to overcome MDR classified on the bases of the fundamental mechanisms of MDR and various approaches to deliver drugs for treatment of MDR cancer.
WOS关键词SENSITIVE POLYMERIC MICELLES ; DOUBLE-STRAND BREAKS ; DRUG-RESISTANCE ; P-GLYCOPROTEIN ; DNA-DAMAGE ; IN-VIVO ; MAGNETIC NANOPARTICLES ; PACLITAXEL DELIVERY ; TARGETED DELIVERY ; ANTICANCER DRUG
资助项目National Basic Research Program of China[2010CB934000] ; National Natural Science Foundation of China[30925041] ; Shanghai Nanomedicine Program[0852nm05700]
WOS研究方向Chemistry
语种英语
WOS记录号WOS:000284078200003
出版者SCIENCE PRESS
源URL[http://119.78.100.183/handle/2S10ELR8/278725]  
专题药物制剂研究中心
通讯作者Li YaPing
作者单位Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714
Bu HuiHui,Gao Yu,Li YaPing. Overcoming multidrug resistance (MDR) in cancer by nanotechnology[J]. SCIENCE CHINA-CHEMISTRY,2010,53(11):2226-2232.
APA Bu HuiHui,Gao Yu,&Li YaPing.(2010).Overcoming multidrug resistance (MDR) in cancer by nanotechnology.SCIENCE CHINA-CHEMISTRY,53(11),2226-2232.
MLA Bu HuiHui,et al."Overcoming multidrug resistance (MDR) in cancer by nanotechnology".SCIENCE CHINA-CHEMISTRY 53.11(2010):2226-2232.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。